Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A PassardiD Amadori

Abstract

We report the results from a first-line phase III randomized clinical trial on metastatic colorectal cancer (mCRC) aimed at evaluating the effectiveness of adding bevacizumab (B) to standard first-line chemotherapy (CT). mCRC patients were randomized to receive first-line CT (FOLFIRI or FOLFOX4) plus B (arm A) or CT only (arm B). The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), response rate (ORR) and safety. Three hundred and fifty patients and 310 events were required to have an 80% statistical power to detect a difference in PFS between the groups. Between November 2007 and March 2012, 376 patients were randomized. About 60% of patients received FOLFOX4 and 40% FOLFIRI. After a median follow-up of 36 months, 343 progressions and 275 deaths had been observed in the overall population. The median PFS was 9.6 [95% confidence interval (CI) 8.2-10.3] and 8.4 (95% CI 7.2-9.0) months for arms A and B, respectively, with a hazard ratio of 0.86 (95% CI 0.70-1.07; P = 0.182). No statistically significant differences in OS or ORR were observed. B-containing regimens were associated with more frequent hypertension, bleeding, proteinuria and asthenia. The addition of B to sta...Continue Reading

References

Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarWilliam F Novotny
Jun 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe ColucciUNKNOWN Gruppo Oncologico Dell'Italia Meridionale
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Randolph HechtRafael G Amado
Feb 7, 2009·The New England Journal of Medicine·Jolien TolCornelis J A Punt
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Niall C TebbuttTimothy J Price
Nov 3, 2010·Clinics in Colon and Rectal Surgery·Rachel A Goodwin, Timothy R Asmis
Nov 15, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Clemens GiessenVolker Heinemann
Jan 11, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roger SidhuSteve Dahlberg
Jul 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S KubickaUNKNOWN ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Apr 30, 2016·BioMed Research International·Suk-Young Lee, Sang Cheul Oh
Mar 17, 2016·Expert Opinion on Drug Safety·Martin D Berger, Heinz-Josef Lenz
Mar 5, 2016·Expert Opinion on Investigational Drugs·M TampelliniG V Scagliotti
Feb 11, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CremoliniA Falcone
Mar 25, 2016·Expert Review of Anticancer Therapy·Timothy J PriceJeremy D Shapiro
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold
Nov 9, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kaitlyn K H GoeyMiriam Koopman
Dec 28, 2016·Journal of Managed Care & Specialty Pharmacy·Rohan C ParikhDavid R Lairson
Jun 10, 2017·International Journal of Molecular Sciences·Paola UliviAlessandro Passardi
Dec 28, 2016·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Jae Hyun Kim, Seun Ja Park
Apr 28, 2018·Future Oncology·Marco TampelliniGiorgio V Scagliotti
Jul 19, 2018·Expert Review of Anticancer Therapy·Timothy J PriceJeremy Shapiro
Aug 4, 2018·Expert Opinion on Drug Safety·Alba NogueridoJosep Tabernero
Sep 2, 2017·Journal of the American Heart Association·Matthias TotzeckTienush Rassaf
Nov 2, 2018·Expert Review of Anticancer Therapy·Per PfeifferCamilla Qvortrup
Feb 26, 2019·Journal of Surgical Oncology·Jaideep SandhuMarwan Fakih
Jul 28, 2019·The Korean Journal of Internal Medicine·Sun Kyung BaekSang-Cheol Lee
Mar 19, 2020·Expert Review of Anticancer Therapy·David K LauTimothy J Price
Jun 21, 2019·Journal of Gastrointestinal Cancer·Tuba KarpuzMehmet Artac
Oct 17, 2017·Oncotarget·Yassine RidouaneBenjamin Haaland
Aug 5, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wentao TangJianmin Xu
Feb 17, 2017·Therapeutic Advances in Medical Oncology·Rachel Riechelmann, Axel Grothey
Jul 11, 2020·Cancer Metastasis Reviews·Gábor LakatosGyörgy Bodoky
Jan 9, 2019·Drugs·Anthony LopezJaffer A Ajani
Mar 29, 2020·Signal Transduction and Targeted Therapy·Yuan-Hong XieJing-Yuan Fang
Aug 6, 2020·Therapeutic Advances in Medical Oncology·Elisabetta PetracciOriana Nanni

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved